{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:49Z","timestamp":1782100189860,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00556-8","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:22:02Z","timestamp":1779186122000},"page":"265-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Intravenous Belimumab in Patients with Systemic Lupus Erythematosus in South Korea: A Multicentre, Observational, Real-World Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Sang-Bae","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Jung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1093","authenticated-orcid":false,"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"556_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/rheumatology\/keaa267","volume":"60","author":"IEM Bultink","year":"2021","unstructured":"Bultink IEM, de Vries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"556_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/rheumatology\/kez516","volume":"59","author":"BT Segura","year":"2020","unstructured":"Segura BT, Bernstein BS, McDonnell T, Wincup C, Ripoll VM, Giles I, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology (Oxford). 2020;59(3):524\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"556_CR3","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1177\/0961203313502571","volume":"22","author":"LA Gonz\u00e1lez","year":"2013","unstructured":"Gonz\u00e1lez LA, Toloza SM, McGwin G Jr., Alarc\u00f3n GS. Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus. 2013;22(12):1214\u201324.","journal-title":"Lupus"},{"issue":"3","key":"556_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3904\/kjim.2018.303","volume":"35","author":"EH Bae","year":"2020","unstructured":"Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, et al. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. Korean J Intern Med. 2020;35(3):652\u201361.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"556_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"556_CR6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/09612033211028653","volume":"30","author":"RA Levy","year":"2021","unstructured":"Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, et al. 10 years of belimumab experience: What have we learnt? Lupus. 2021;30(11):1705\u201321.","journal-title":"Lupus"},{"issue":"6","key":"556_CR7","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","volume":"180","author":"MJ Benson","year":"2008","unstructured":"Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180(6):3655\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"556_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78(3):355\u201366.","journal-title":"Drugs"},{"key":"556_CR9","unstructured":"GSK. Annex I summary of product characteristics. European Medicines Agency. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed 1 Nov 2024."},{"key":"556_CR10","unstructured":"GSK. Highlights of prescribing information: Benlysta (belimumab). 2024. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF. Accessed 1 Nov 2024."},{"key":"556_CR11","unstructured":"MFDS. Benlysta prescribing information. 2013. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=201307774. Accessed 12 Nov 2024."},{"issue":"3","key":"556_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355\u201363.","journal-title":"Ann Rheum Dis"},{"key":"556_CR13","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Bae SC, Bass D, Curtis P, Chu M, DeRose K, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 2021;7(2).","DOI":"10.1136\/rmdopen-2021-001629"},{"issue":"1","key":"556_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14997","volume":"27","author":"CH Suh","year":"2024","unstructured":"Suh CH, Lee Y, Yoo SB, Quasny H, Navarro Rojas AA, Hammer A, et al. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia. Int J Rheum Dis. 2024;27(1):e14997.","journal-title":"Int J Rheum Dis"},{"key":"556_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030962","author":"F Sun","year":"2023","unstructured":"Sun F, Wu H, Wang Z, Wu T, Wu X, Chen J, et al. Effectiveness and safety of belimumab in Chinese lupus patients: a multicenter, real-world observational study. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11030962.","journal-title":"Biomedicines"},{"issue":"1","key":"556_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/rheumatology\/kead629","volume":"64","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Qi F, Bai J, Zhang N, Yang T, Sun W, et al. Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single centre in China. Rheumatology (Oxford). 2025;64(1):108\u201316.","journal-title":"Rheumatology (Oxford)"},{"key":"556_CR17","unstructured":"GSK study register. Clinical Study Report: HGS1006-C1057.CSR. https:\/\/www.gsk-studyregister.com\/trials\/HGS1006-C1057."},{"issue":"9767","key":"556_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u201331.","journal-title":"Lancet"},{"issue":"12","key":"556_CR19","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918\u201330.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"556_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000529675","volume":"9","author":"M Tan","year":"2023","unstructured":"Tan M, Xu J, Tan Y, Qu Z, Yu F, Zhao M. Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China. Kidney Dis. 2023;9(3):218\u201328.","journal-title":"Kidney Dis"},{"issue":"1","key":"556_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10067-023-06817-z","volume":"43","author":"S Zhang","year":"2024","unstructured":"Zhang S, Qiu Q, Zeng S, Li H, Xu L, Jie L, et al. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study. Clin Rheumatol. 2024;43(1):199\u2013208.","journal-title":"Clin Rheumatol"},{"issue":"14","key":"556_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/09612033241299175","volume":"33","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Ye Z, He S, Tang L, Xie C, Yin S, et al. Belimumab safety in adult and paediatric Chinese patients with systemic lupus erythematosus: a Phase 4, multicentre, observational study. Lupus. 2024;33(14):1562\u201372.","journal-title":"Lupus"},{"issue":"3","key":"556_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","volume":"81","author":"X Yu","year":"2023","unstructured":"Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, et al. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population. Am J Kidney Dis. 2023;81(3):294-306 e1.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"556_CR24","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","volume":"3","author":"SZ Sheikh","year":"2021","unstructured":"Sheikh SZ, Scheinberg MA, Wei JC, Tegzova D, Stohl W, de Toledo RA, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021;3(2):e122\u201330.","journal-title":"Lancet Rheumatol."},{"issue":"2","key":"556_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/mr\/road030","volume":"34","author":"X Zhao","year":"2024","unstructured":"Zhao X, Wu H, Li S, Gao C, Wang J, Ge L, et al. The impact of the COVID-19 pandemic on SLE. Mod Rheumatol. 2024;34(2):247\u201364.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"556_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12026-023-09449-2","volume":"72","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Wu T, Huang D, Wu J, Zhang W, et al. COVID-19 in systemic lupus erythematosus patients treated with belimumab: a retrospective clinical study. Immunol Res. 2024;72(3):418\u201329.","journal-title":"Immunol Res"},{"issue":"2","key":"556_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/rheumatology\/kead707","volume":"64","author":"S Lin","year":"2023","unstructured":"Lin S, Zhang J, You X, Chen B, Liang Y, Zhou Y, et al. Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study. Rheumatology. 2023;64(2):614\u201322.","journal-title":"Rheumatology"},{"key":"556_CR28","doi-asserted-by":"crossref","unstructured":"Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, et al. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: a real-life, multicentre observational study. Front Immunol. 2023;13(2022).","DOI":"10.3389\/fimmu.2022.1074044"},{"issue":"1","key":"556_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41927-024-00452-0","volume":"9","author":"AM Lila","year":"2025","unstructured":"Lila AM, Aseeva EA, Zagrebneva AI, Vinogradova IB, Samigullina RR, Khamashta M, et al. Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation. BMC Rheumatol. 2025;9(1):4.","journal-title":"BMC Rheumatol"},{"issue":"4","key":"556_CR30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","volume":"7","author":"CE Collins","year":"2020","unstructured":"Collins CE, Cortes-Hern\u00e1ndez J, Garcia MA, von Kempis J, Schwarting A, Touma Z, et al. Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve studies. Rheumatol Ther. 2020;7(4):949\u201365.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"556_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000118","volume":"3","author":"CE Collins","year":"2016","unstructured":"Collins CE, Dall\u2019Era M, Kan H, Macahilig C, Molta C, Koscielny V, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3(1):e000118.","journal-title":"Lupus Sci Med."},{"key":"556_CR32","unstructured":"RMP. Regulation on approval and review of biological products. 2015. https:\/\/www.mfds.go.kr\/eng\/brd\/m_27\/view.do?seq=71480&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1. Accessed 3 Nov 2024."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00556-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00556-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00556-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:39Z","timestamp":1782098379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00556-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00556-8","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"27 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by GSK (Study 216984).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S-BY\n                      and\n                      E-BL\n                      are employed by GSK.\n                      J-EC\n                      and\n                      D-JB\n                      are employed by GSK and hold financial equities in GSK.\n                      S-HP\n                      ,\n                      S-HK\n                      ,\n                      EYL\n                      ,\n                      Y-AL\n                      and\n                      S-CB\n                      report no conflicting interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"This manuscript has no associated data. For requests for access to anonymized subject-level data, please contact the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethical approval was obtained from the Ministry of Food and Drug Safety for the study, in accordance with the risk management plan (RMP). The RMP for IV belimumab was in accordance with Article 7-2 of the regulation on approval and examination of biological products [\n                      \n                      ]. This study was conducted in accordance with regulatory requirements including institutional review board approval (Institutional Review Board of Hanyang University Hospital; 2021-04-023-002), Declaration of Helsinki 2008 and its later amendments, patient informed consent and investigator reporting requirements. Approval was obtained from the Institutional Review Board or Ethics Committee at each of the 18 participating study sites.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Consent was obtained prior to the start of the study from each participating patient.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"S-BY, J-EC, D-JB and E-BL contributed to the conception or design of the study. S-HP, S-HK, EYL, Y-AL and S-CB contributed to the acquisition of data. S-BY, J-EC and E-BL contributed to data analysis and interpretation. All authors critically reviewed and approved the final version of this manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}